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educational value of such an event is particularly interesting and 
future studies of larger medical student groups are warranted. 
 
130 
TACKLING CULTURAL AND SOCIAL CHANGE: AN EXAMPLE OF A 
SUCCESSFUL QUALITY IMPROVEMENT INITIATIVE TO ENHANCE 
PATIENT SAFETY  




Purpose: This presentation will describe a quality improvement 
initiative that occurred in radiation therapy departments across 
British Columbia. This initiative harnessed the investigational 
response to several safety events in the province. The 
reformative change involved the implementation of a Provincial 
Patient Identification Policy specific to radiation therapy 
delivery, across multiple centres with different operational 
needs. 
Methods and Materials: The operationalization of the Provincial 
Patient Identification Policy utilized quality improvement 
fundamentals from the Plan-Do-Study-Act model. This initiative 
involved not only a simple procedural change, but also 
challenged deeply held beliefs and assumptions of Radiation 
Therapists in British Columbia. Radiation Therapists believed 
strongly that involving patients in daily identification protocols 
would create barriers to developing rapport and trust. As such, 
education involving the patient identification policy had to 
tackle the social aspects of change implementation, as well as 
the increasing effort to focus on improving patient experience by 
health care providers. Early on, this was recognized by Clinical 
Educators, and actively addressed. Transformative education 
took place which challenged the learners to examine their beliefs 
about patient perspectives and how this related to patient 
safety. Efforts to educate about the change were well 
coordinated with the implementation of the change itself. After 
the initial change, formal avenues for feedback were provided, 
and the procedures were refined. After several months, a 
provincial audit was performed. 
Results: Preliminary audits performed on patient identification 
at two radiation therapy centres indicate that the 
implementation of the Provincial Patient Identification Policy 
has been a success. Two types of audits were carried out, these 
will be described. 
Conclusions: Identifying and addressing the social aspects of 
change implementation is key to ensuring the success of quality 
improvement initiatives. Despite common myths and anecdotal 
evidence from Radiation Therapists, patients have appreciated 
their active involvement in daily treatment and safety checks.  
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THE HURDLES TO ONE HUNDRED: BARRIERS TO PEER REVIEW IN 
RADIATION ONCOLOGY  
Brian Liszewski, Ruby Bola 
Odette Cancer Centre, Toronto, ON 
 
Purpose: Peer review is the evaluation of the creative work or 
performance by other people in the same field to enhance the 
quality of work, or performance. In an effort to improve quality 
and standardization, a number of initiatives have been put in 
place at the national and provincial levels. In 2011 and updated 
in 2013, the Canadian Partnership for Quality Radiotherapy 
(CPQR) published Quality Assurance Guidelines for Canadian 
Radiation Treatment Programs. This document recommends that 
all radiation treatment plans administered with adjuvant or 
curative intent, and others plans where there is a significant 
potential for adverse patient outcome, undergo Radiation 
Oncologist peer review. The aim of this project was to identify 
and mitigate the barriers to an effective peer review program, 
to achieve the recommendations set forth in the CPQR guidance 
document. 
Methods and Materials: A large urban comprehensive cancer 
centre performed peer review employing a site group model. 10 
site groups are represented meeting on a weekly basis. A three 
month retrospective analysis was performed identifying all cases 
treated within the time period. Each case was characterized by: 
site; month; referral to review; and review status. Cases not 
referred for review and or did not undergo peer review were 
examined for barriers to successful peer review. 
Results: The average peer review rate for the three month time 
period was 85.43%. 16.61% of patients did not receive a referral 
to peer review. 3.38% of patients were referred for review, 
however did not undergo peer review. Identified barriers to 
successful peer review included; human error, workload, 
resource limitations and culture change. 
Conclusions: Peer review; has the potential to identify errors; 
serves as a forum for continuing education; and catalyzes 
standardization. By mitigating the barriers to peer review 
including; human error; workload; resource limitations; and 
adopting a culture promoting the initiative an increasing number 
of cases can be successfully reviewed, resulting in a high fidelity 
system to increase patient safety. 
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Purpose: The National System for Incident Reporting in Radiation 
Therapy (NSIR-RT) is an initiative between the Canadian 
Partnership for Quality Radiotherapy (CPQR) in partnership with 
the Canadian Institute of Health Information (CIHI). Cancer Care 
Ontario (CCO) has an established a Radiation Incident Safety 
Committee (RISC) with the goal of reducing the impact of 
radiation incidents across the province’s 14 radiation treatment 
programs (RTP)s. CCO RISC has assessed its collective incident 
reporting processes in comparison to the provincial adoption of 
the NSIR-RT. 
Methods and Materials: Facilitated by a face-to-face meeting of 
Primary Radiation Incident Leads (RILs), an assessment of current 
incident reporting processes of each regional radiation program 
was performed. Reporting tools, taxonomies and processes were 
collected for each of the 14 RPTs. The RILs met to discuss the 
current state of reporting in comparison to the CPQR proposed 
NSIR-RT. Benefits and barriers to the provincial adoption of the 
NSIR-RT platform were identified. 
Results: 100% of RTPs had an established incident reporting 
process. 85% of RTPs reported radiation therapy incidents using 
software databases. Nine software systems were identified 
(three of which were developed in house) for the facilitation of 
incident learning. In addition, 100% of RTPs had locally specific 
incident reporting taxonomies. Evaluating the proposed NSIR-RT 
the following benefits and barriers were identified. 
 
Benefits: 
• Access to provincial dataset 
• Unified taxonomy 
• Cost neutral 
• Reduced provincial reporting requirements 
Barriers: 
• Corporate buy-in 
• Multiple data entry requirements/resources 
• Access to provincial data-set 
• Measures of success 
 
Conclusions: Currently, 35% of RTPs are using NSIR-RT and 35% 
are in the progress of completing service agreements. In 
addition, work with CIHI to develop a CCO administrator role to 
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access provincial data is underway. The RISC continues to work 
through the NSIR-RT pilot to mitigate the identified barriers in 
an effort to improve provincially provided care. 
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PREDICTORS OF NODAL RESPONSE AFTER NEOADJUVANT 
CHEMORADIOTHERAPY FOR RECTAL ADENOCARCINOMA; A 
RETROSPECTIVE STUDY 
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Purpose: Pathological response to neoadjuvant therapy has been 
linked to long-term outcome in rectal cancer (RC). Predicting 
nodal response is important especially in cases where watch and 
wait strategy is being considered. This study was carried out to 
identify potential predictors of pathological nodal response after 
long course chemoradiotherapy (CRT). 
Methods and Materials: A retrospective review of all patients 
with clinically node positive RC who received neoadjuvant CRT 
in Manitoba between January 2007 and December 2012 was 
conducted. Pre CRT tumour staging, treatment-related 
hematologic toxicities and pathologic nodal response data were 
recorded. Univariable and Multivariable analyses were 
performed using Bayesian logistic regression models. 
Results: Two hundred and six patients with clinically node 
positive RC were included in this study. The mean number of 
excised nodes was 16.35. One hundred and seventeen patients 
(56.8%) achieved a pathologic complete nodal response. Higher 
pre-treatment carcinoembryonic antigen (CEA) level (p = 0.0072) 
and presence of lymphovascular space invasion (LVI) in the 
surgical specimen (p = 0.0002) were independent predictors of 
lack of nodal response. In the univariable analysis, there was a 
tendency to a better response in patients who developed less 
treatment-induced lymphocytopenia. 
Conclusions: Pre-treatment CEA and presence of LVI predicted 
less pathological nodal response post CRT for rectal cancer. LVI 
is a pathological finding, however, signs of vascular invasion can 
be detected on the pre-treatment MRI. These results could 
potentially be used to identify favourable responders to CRT and 
guide management strategies of rectal cancer especially when 
organ and function preservation are pursued. 
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Purpose:  Stereotactic body radiotherapy (SBRT) can treat 
hepatocellular (HCC) patients who are not eligible for surgery, 
trans-arterial chemoembolization or radiofrequency ablation. 
This study aims to compare the efficacy and toxicity of SBRT to 
small tumours (< 4.4 cm, our median population size) and 
moderate to large tumours (≥ 4.4 cm). 
Methods and Materials: A retrospective study of the first 48 
provincially treated HCC patients (March 2011-July 2015) was 
conducted. All patients were discussed at multidisciplinary 
rounds and considered ineligible for further standard local 
therapies. Local control (LC), progression free survival (PFS), 
overall survival (OS) and toxicities were analyzed. 
Results: Fifty-one separate hepatomas were treated with a 
median size of 4.4cm (range: 1.3-15.6cm). Baseline 
demographics, performance status, previous liver-directed 
treatments, and Child’s Pugh (CP) score were similar between 
the groups. Hepatitis B was more common in the ≥4.4cm group 
while Hepatitis C was more common in the < 4.4 cm group (p = 
0.05). RT doses were 36 to 50 Gy in three to 10 fractions, with 
87% of patients receiving 45 Gy in 3 or 5 fractions. Twenty-eight 
(55%) hepatomas were treated with a biological equivalent dose 
(BED10) ≥ 100 Gy and 45 (88.3%) were treated with a BED10 ≥ 80 
Gy. Tumours <4.4cm were more likely to be treated with a BED10 
≥ 80 Gy (p < 0.001). Seven patients (15%) had worsened CP score 
by > 1 point at three months post-SBRT, but this was not different 
between the two groups (p = 0.86). LC for all patients was 94% 
at one and two years, and was comparable for tumours < 4.4 cm 
and ≥ 4.4 cm (two year LC: 96% for < 4.4 cm versus 92% for ≥ 4.4 
cm, p = 0.91). OS for all patients was 65% at two years (87% for 
< 4.4 cm versus 46% for ≥ 4.4 cm, p = 0.07). PFS was 38% at two 
years for all patients, and did not differ significantly between 
groups (p = 0.70). On univariate analysis, BED10 ≥ 80 Gy was the 
only factor associated with improved PFS, while both BED10 ≥ 80 
Gy and normal baseline AFP were associated with improved OS. 
Conclusions: SBRT provides high local control for patients with 
inoperable HCC and can be delivered with acceptable risk for 
post-treatment hepatic injury even for moderate to large sized 
tumours. Radiation doses above BED10 of 80 Gy improved PFS 
and OS in our cohort. 
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Purpose: Concurrent chemoradiation (CRT) with fluorouracil (5-
FU) and mitomycin C (MMC) is standard treatment for anal canal 
carcinoma (ACC). However, treatment varies based on available 
RT technology and centre preference for chemotherapy (CT) 
regimen. The purpose of this study was to compare dosimetric 
parameters, toxicity, and outcomes in ACC patients treated with 
two different RT modalities and CT regimens. 
Methods and Materials: This is a retrospective study of 
consecutive ACC patients treated with radical CRT at two 
tertiary cancer centres from 2008-2012. Patients were grouped 
according to RT modality (IMRT versus HT), and CT regimen (5-
FU with: one cycle MMC, MMC1 versus two cycles, MMC2). 
Primary endpoints were dosimetric comparison between the RT 
cohorts and toxicity comparison between the CT cohorts; 
secondary endpoint was comparison of outcomes, including 
patterns of failure, disease-free survival (DFS), overall survival 
(OS), colostomy-free survival (CFS). 
Results: Of 64 patients in total, 34 (53%) were treated with IMRT 
and 30 (47%) with HT. Patient and tumour characteristics were 
not significantly different between the groups. Twenty-six 
patients (43%) received MMC1, while 34 (57%) patients received 
MMC2; 4 patients received 5FU/cisplatin. The majority (25/34, 
74%) of IMRT patients received MMC1, while most HT patients 
(29/30, 97%) received MMC2 (p < 0.01), which correlated with 
treatment centre. HT achieved more homogenous coverage of 
the primary tumour (HT homogeneity and uniformity index 0.15 
and 1.03 versus 0.29 and 1.06 for IMRT, p < 0.01 and p < 0.01). 
IMRT achieved better bladder, femoral head and peritoneal 
space sparing, and lower skin dose (p < 0.01 for all). HT achieved 
lower bone marrow and external genitalia dose (both p < 0.01) 
versus IMRT. Comparing CT regimens, MMC2 was more strongly 
associated with Grade 2+ neutropenia (p = 0.03) and Grade 4 
toxicity (p = 0.03) versus MMC1. There were no differences in 
local, regional or distant failure based on RT modality (p = 0.46, 
p = 0.62, p = 0.12, respectively) or CT regimen (p = 1.0, p = 0.31, 
p = 0.16). Additionally, there were no differences in OS, DFS or 
